Cocrystal Pharma Inc (COCP)

$1.05 -0.01 (-0.94%)
Market Cap 13.79M
Revenue (ttm) 0.00
Net Income (ttm) -8.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 112,100
Avg Vol 150,840
Day's Range N/A - N/A
Shares Out 13.79M
Stochastic %K 79%
Beta 1.42
Analysts Strong Sell
Price Target $8.00

Company Profile

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in ph...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 262 7123
Address:
19805 North Creek Parkway, Bothell, United States
DOUG_Called_It
DOUG_Called_It Jun. 23 at 9:40 PM
$COCP just drop already, getting boring
0 · Reply
Thrasher5699
Thrasher5699 Jun. 23 at 8:13 PM
$COCP I only have 10k shares but this could make us rich if they can pull this off!
0 · Reply
elon_musk22
elon_musk22 Jun. 23 at 5:28 PM
$COCP Going to be so quick and so much fun $25 plus
0 · Reply
DaphneBrooke
DaphneBrooke Jun. 23 at 2:55 PM
$COCP Starting to look interesting. Cheap shares.
0 · Reply
elon_musk22
elon_musk22 Jun. 17 at 3:55 PM
$COCP July 17 2020 player bulmar LMFAO😂 let's go baby! jai wei 🤡
0 · Reply
bulmar
bulmar Jun. 17 at 3:06 PM
$COCP surging
0 · Reply
DOUG_Called_It
DOUG_Called_It Jun. 16 at 6:38 PM
$COCP lol
0 · Reply
elon_musk22
elon_musk22 Jun. 16 at 6:22 PM
$COCP time to buy this desperate seller final shares
0 · Reply
elon_musk22
elon_musk22 Jun. 16 at 5:28 PM
$COCP Let's go baby! you go girl Jai Wei your such a bad ass tiny winny player LMfaooo largest position in 2020 after chasing a covid stock and never selling LMFAO🤣
0 · Reply
elon_musk22
elon_musk22 Jun. 16 at 5:11 PM
$COCP $25 real soon how bouts that new antiviral CEO
0 · Reply
Latest News on COCP
Cocrystal co-CEOs Sam Lee and Jim Martin step down, James Sapirstein succeeds

2026-06-03T11:14:05.000Z - 21 days ago

Cocrystal co-CEOs Sam Lee and Jim Martin step down, James Sapirstein succeeds

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

Jun 3, 2026, 7:00 AM EDT - 21 days ago

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

Cocrystal Pharma announces discovery of pan-viral inhibitors targeting viruses

2026-05-26T12:20:21.000Z - 4 weeks ago

Cocrystal Pharma announces discovery of pan-viral inhibitors targeting viruses

Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

May 26, 2026, 8:00 AM EDT - 4 weeks ago

Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

May 15, 2026, 8:00 AM EDT - 5 weeks ago

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection

Apr 30, 2026, 4:05 PM EDT - 7 weeks ago

Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection

Cocrystal Pharma files $150M mixed securities shelf

2026-04-23T23:25:20.000Z - 2 months ago

Cocrystal Pharma files $150M mixed securities shelf

Cocrystal Pharma receives FDA Fast Track designation for CDI-988

2026-04-02T12:22:27.000Z - 2 months ago

Cocrystal Pharma receives FDA Fast Track designation for CDI-988

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive

Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma announces first subjects dosed in Phase 1b study of CDI-988

2026-03-09T12:10:09.000Z - 3 months ago

Cocrystal Pharma announces first subjects dosed in Phase 1b study of CDI-988

First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Mar 9, 2026, 8:00 AM EDT - 3 months ago

First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

Feb 19, 2026, 8:00 AM EST - 4 months ago

Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

Cocrystal Pharma receives IRB approval from Emory University for Phase 1b trial

2025-12-18T13:16:41.000Z - 6 months ago

Cocrystal Pharma receives IRB approval from Emory University for Phase 1b trial

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

Dec 18, 2025, 8:00 AM EST - 6 months ago

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference

Dec 1, 2025, 8:00 AM EST - 7 months ago

Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference

Cocrystal Pharma reports Q3 EPS (19c) vs (49c) last year

2025-11-14T13:11:15.000Z - 7 months ago

Cocrystal Pharma reports Q3 EPS (19c) vs (49c) last year

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Nov 14, 2025, 8:00 AM EST - 7 months ago

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma completes $1.03M private placement

2025-10-30T12:26:32.000Z - 8 months ago

Cocrystal Pharma completes $1.03M private placement

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules

Oct 30, 2025, 8:00 AM EDT - 8 months ago

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules

Cocrystal Pharma receives NIH SBIR award to advance influenza inhibitor program

2025-10-27T12:20:43.000Z - 8 months ago

Cocrystal Pharma receives NIH SBIR award to advance influenza inhibitor program

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

Oct 27, 2025, 8:00 AM EDT - 8 months ago

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

Oct 2, 2025, 8:00 AM EDT - 9 months ago

Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

Cocrystal Pharma files to sell 5.74M shares of common stock for holders

2025-09-19T20:35:11.000Z - 9 months ago

Cocrystal Pharma files to sell 5.74M shares of common stock for holders

Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 15, 2025, 4:30 PM EDT - 10 months ago

Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Cocrystal Pharma announces up to $13M registered direct offering

2025-09-12T13:45:10.000Z - 10 months ago

Cocrystal Pharma announces up to $13M registered direct offering

Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 12, 2025, 9:43 AM EDT - 10 months ago

Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Cocrystal Pharma showcases CDI-988, antiviral for norovirus infection

2025-09-12T12:10:38.000Z - 10 months ago

Cocrystal Pharma showcases CDI-988, antiviral for norovirus infection

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference

Sep 12, 2025, 8:00 AM EDT - 10 months ago

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference

Cocrystal Pharma receives IND clearance for challenge study of CDI-988

2025-09-08T12:05:24.000Z - 10 months ago

Cocrystal Pharma receives IND clearance for challenge study of CDI-988

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment

Sep 8, 2025, 8:00 AM EDT - 10 months ago

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 10 months ago

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

Cocrystal Pharma reports Q2 EPS (20c), consensus (30c)

2025-08-14T12:15:44.000Z - 11 months ago

Cocrystal Pharma reports Q2 EPS (20c), consensus (30c)

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma presents Phase 1 results for CDI-988

2025-08-05T12:26:50.000Z - 11 months ago

Cocrystal Pharma presents Phase 1 results for CDI-988

Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

Jul 10, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

Cocrystal Pharma price target lowered to $6 from $7 at H.C. Wainwright

2025-06-20T10:10:30.000Z - 1 year ago

Cocrystal Pharma price target lowered to $6 from $7 at H.C. Wainwright

Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference

Cocrystal announces CC-42344 active against 204 Texas H5N1 avian influenza

2025-05-29T12:10:22.000Z - 1 year ago

Cocrystal announces CC-42344 active against 204 Texas H5N1 avian influenza

Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

May 29, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference

May 28, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference

Cocrystal Pharma reports Q1 EPS (23c) vs (39c) last year

2025-05-15T12:08:39.000Z - 1 year ago

Cocrystal Pharma reports Q1 EPS (23c) vs (39c) last year

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

May 15, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma’s norovirus oral candidate demonstrates ‘potent activity’

2025-04-24T12:20:57.000Z - 1 year ago

Cocrystal Pharma’s norovirus oral candidate demonstrates ‘potent activity’

Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

Mar 6, 2025, 8:00 AM EST - 1 year ago

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Dec 31, 2024, 8:00 AM EST - 1 year ago

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

Aug 19, 2024, 4:05 PM EDT - 2 years ago

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

Aug 15, 2024, 3:00 PM EDT - 2 years ago

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

May 13, 2024, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

May 1, 2024, 8:00 AM EDT - 2 years ago

Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Mar 5, 2024, 8:30 AM EST - 2 years ago

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

Dec 6, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Nov 29, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

Nov 27, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Nov 9, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

Sep 5, 2023, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Apr 10, 2023, 8:30 AM EDT - 3 years ago

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023

Mar 22, 2023, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023

Cocrystal Pharma Announces Participation in Virtual Investor Events

Jan 26, 2023, 8:00 AM EST - 3 years ago

Cocrystal Pharma Announces Participation in Virtual Investor Events

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

Jan 23, 2023, 9:00 AM EST - 3 years ago

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

Dec 1, 2022, 4:05 PM EST - 3 years ago

Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Nov 17, 2022, 8:00 AM EST - 3 years ago

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

DOUG_Called_It
DOUG_Called_It Jun. 23 at 9:40 PM
$COCP just drop already, getting boring
0 · Reply
Thrasher5699
Thrasher5699 Jun. 23 at 8:13 PM
$COCP I only have 10k shares but this could make us rich if they can pull this off!
0 · Reply
elon_musk22
elon_musk22 Jun. 23 at 5:28 PM
$COCP Going to be so quick and so much fun $25 plus
0 · Reply
DaphneBrooke
DaphneBrooke Jun. 23 at 2:55 PM
$COCP Starting to look interesting. Cheap shares.
0 · Reply
elon_musk22
elon_musk22 Jun. 17 at 3:55 PM
$COCP July 17 2020 player bulmar LMFAO😂 let's go baby! jai wei 🤡
0 · Reply
bulmar
bulmar Jun. 17 at 3:06 PM
$COCP surging
0 · Reply
DOUG_Called_It
DOUG_Called_It Jun. 16 at 6:38 PM
$COCP lol
0 · Reply
elon_musk22
elon_musk22 Jun. 16 at 6:22 PM
$COCP time to buy this desperate seller final shares
0 · Reply
elon_musk22
elon_musk22 Jun. 16 at 5:28 PM
$COCP Let's go baby! you go girl Jai Wei your such a bad ass tiny winny player LMfaooo largest position in 2020 after chasing a covid stock and never selling LMFAO🤣
0 · Reply
elon_musk22
elon_musk22 Jun. 16 at 5:11 PM
$COCP $25 real soon how bouts that new antiviral CEO
0 · Reply
elon_musk22
elon_musk22 Jun. 16 at 5:11 PM
$COCP the scary shorter X DOUG X - Whatever happened x Doug x account?? This is loser dude guy who pretends he is short but in the meantime back in April 🤡 Lmfaoo😭 pumped lcid for 6 yrs and wanted to sell friggin T-shirts but watch out on his short MEANWHILE the real shorts covered 1 Milly shares already now basically nothing
0 · Reply
Ultimate1trader
Ultimate1trader Jun. 16 at 4:05 PM
$COCP Its time for NEWS
1 · Reply
DOUG_Called_It
DOUG_Called_It Jun. 16 at 3:27 PM
$COCP there she goes, come to papa… I think momo and listened to me and come to the dark side
0 · Reply
DOUG_Called_It
DOUG_Called_It Jun. 15 at 6:31 PM
$COCP he will come back soon, chant how it’s going to $5 soon …. And the the RS comes… same same… whoever is invested here is paying his salary I think. Since the company pays for him to pump this crap
0 · Reply
DOUG_Called_It
DOUG_Called_It Jun. 15 at 5:03 PM
$COCP 🙂momo, where are you?
1 · Reply
bulmar
bulmar Jun. 15 at 4:53 PM
$COCP Of course this turd goes down.
0 · Reply
elon_musk22
elon_musk22 Jun. 15 at 12:07 PM
$COCP BULMAR. Your pumped this as your largest position 6 yrs ago. Never sold it. Why Not? You call yourself a technical trader. That's a lie. Now you own 100 shares. Try selling other morons your fake news. Blaming others for never making money and buying covid stocks and never selling shame on you dummy LMFAO Meanwhile. The company has succeeded in PHASE 2. IF you knew what you invested in they had their HCV drug in phase 2 and phase 2 combo success. They just didn't get partner in a crowded field. So they had to pivot. Total Idiot.
0 · Reply
elon_musk22
elon_musk22 Jun. 11 at 9:15 PM
$COCP See you at $25 - misserable person former "x Doug x " account deleted his account after losing all his money on (2) stocks is jealous why? He can't afford to buy any more stocks and pretends he is smart LMFAOLMFAO😂 38 Posts = All bash one name 🤡
0 · Reply
DOUG_Called_It
DOUG_Called_It Jun. 11 at 8:21 PM
$COCP get out get out as soon as you can, big red is on its way
0 · Reply
elon_musk22
elon_musk22 Jun. 11 at 3:03 PM
$COCP currently largest position, let's go baby! LMFAO😂
0 · Reply
bulmar
bulmar Jun. 11 at 2:14 PM
$COCP MS101. Had a price target of 100 a few years back. Hassan hasn’t really done anything to this point as reflected in the share price. Mark could be a paid insider as he pumps constantly and guaranteed results that never come.He was totally good with the 1-12 reverse split and constant offerings . See his history for yourself. Could a miracle happen sure…. With this management same old garbage pan viral everything.. Never a stage 2 or 3 winner.
0 · Reply
Crazystocks25
Crazystocks25 Jun. 10 at 5:18 PM
$COCP back 0.7
1 · Reply